Literature DB >> 15502409

Fluconazole-resistant pathogens Candida inconspicua and C. norvegensis: DNA sequence diversity of the rRNA intergenic spacer region, antifungal drug susceptibility, and extracellular enzyme production.

Takashi Sugita1, Kanji Takeo, Misako Ohkusu, Eric Virtudazo, Masako Takashima, Emi Asako, Fumiko Ohshima, Satoshi Harada, Chikako Yanaka, Akemi Nishikawa, Laszlo Majoros, Matthias Sipiczki.   

Abstract

The opportunistic fungal pathogens Candida inconspicua and C. norvegensis are very rarely isolated from patients and are resistant to fluconazole. We collected 38 strains of the two microorganisms isolated from Europe and Japan, and compared the polymorphism of the rRNA intergenic spacer (IGS) and internal transcribed spacer (ITS) regions, antifungal drug susceptibility, and extracellular enzyme production as a potential virulence factor. While the IGS sequences of C. norvegensis were not very divergent (more than 96.7% sequence similarity among the strains), those of C. inconspicua showed remarkable diversity, and were divided into four genotypes with three subtypes. In the ITS region, no variation was found in either species. Since the sequence similarity of the two species is approximately 70% at the ITS region, they are closely related phylogenetically. Fluconazole resistance was reconfirmed for the two microorganisms but they were susceptible to micafungin and amphotericin B. No strain of either species secreted aspartyl proteinase or phospholipase B. These results provide basal information for accurate identification, which is of benefit to global molecular epidemiological studies and facilitates our understanding of the medical mycological characteristics of C. inconspicua and C. norvegensis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502409     DOI: 10.1111/j.1348-0421.2004.tb03602.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  7 in total

Review 1.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.

Authors:  Andrew M Borman; Julian Muller; Jo Walsh-Quantick; Adrien Szekely; Zoe Patterson; Michael D Palmer; Mark Fraser; Elizabeth M Johnson
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; D Ellis; V Tullio; A Rodloff; W Fu; T A Ling
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

4.  High-throughput identification and quantification of Candida species using high resolution derivative melt analysis of panfungal amplicons.

Authors:  Tasneem Mandviwala; Rupali Shinde; Apoorv Kalra; Jack D Sobel; Robert A Akins
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

5.  In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy.

Authors:  Narcisa Mandras; Vivian Tullio; Valeria Allizond; Daniela Scalas; Giuliana Banche; Janira Roana; Francesca Robbiano; Giacomo Fucale; Aurelio Malabaila; Anna Maria Cuffini; Nicola Carlone
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

6.  Phylogenetic relationships matter: antifungal susceptibility among clinically relevant yeasts.

Authors:  A F Schmalreck; M Lackner; K Becker; W Fegeler; V Czaika; H Ulmer; C Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

7.  Treatment of invasive candidiasis in the elderly: a review.

Authors:  Aikaterini Flevari; Maria Theodorakopoulou; Aristea Velegraki; Apostolos Armaganidis; George Dimopoulos
Journal:  Clin Interv Aging       Date:  2013-09-09       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.